Tissue-spreader assembly

Information

  • Patent Grant
  • 11937796
  • Patent Number
    11,937,796
  • Date Filed
    Thursday, June 17, 2021
    2 years ago
  • Date Issued
    Tuesday, March 26, 2024
    a month ago
Abstract
A tissue-spreader assembly is configured to be selectively inserted into a patient having a first biological tissue and a second biological tissue, and to be maneuvered proximate to the second biological tissue. The tissue-spreader assembly is also configured to selectively engage, at least in part, an area of the second biological tissue without engaging the first biological tissue. The tissue-spreader assembly is also configured to selectively spread, at least in part, the area of the second biological tissue, and maintain the area of the second biological tissue in a spread-apart condition after the tissue-spreader assembly, in use, selectively engages, at least in part, the area of the second biological tissue.
Description
TECHNICAL FIELD

This document relates to the technical field of (and is not limited to) a tissue-spreader assembly (and method therefor).


BACKGROUND

Known medical devices are configured to facilitate a medical procedure and help healthcare providers diagnose and/or treat medical conditions of sick patients.


SUMMARY

It will be appreciated that there exists a need to mitigate (at least in part) at least one problem associated with the existing (known) tissue spreaders (also called the existing technology). After much study of, and experimentation with, the existing (known) tissue spreaders, an understanding (at least in part) of the problem and its solution have been identified (at least in part) and are articulated (at least in part) as follows:


Gaining epicardial access involves piercing the thin pericardial layer that surrounds the heart (of the patient) without puncturing the myocardium (the heart muscle that is encapsulated by the pericardial layer). This might be likened to trying to puncture a thin layer of plastic wrap surrounding (wrapped around) a steak without puncturing (or damaging) the steak itself.


Known mechanical needles are configured to puncture the pericardium layer, where the user might be required to precisely control the amount of input force and/or displacement to be applied to the pericardium layer (via the needle, etc.) in order to avoid inadvertently puncturing (damaging) the myocardium.


Sometimes, the amount of force input required to puncture the pericardium layer might be the same as, or similar to, the amount of force input required to puncture the myocardium. Given that the pericardium layer and the myocardium layer are in such close proximity to one another, it might be unavoidable to puncture the myocardium layer (while puncturing the pericardium layer) when trying to gain epicardial access (in the heart of the patient).


For instance, there are known devices configured to pull the pericardium layer back from the myocardium layer in order to facilitate easier and safer puncturing of the pericardium layer. In doing this, the known devices might stretch a region of the pericardium layer, increasing the stress in the tissue and making the pericardium layer easier to puncture. These known devices embed themselves in the pericardial layer (tissue) in order to gain a foothold and allow a user to separate the two tissues (the pericardium layer and the myocardium layer). Along these same lines, if a device gains a foothold (or differentially grip) the pericardium layer from the myocardium layer, and uses the grip to spread out the pericardium layer over top of the myocardium layer, it might increase the stress in the pericardium layer relative to the myocardium layer, and facilitate easier (less risky) puncturing of the pericardium layer without inadvertently imparting damage to the myocardium layer.


To mitigate, at least in part, at least one problem associated with the existing technology, there is provided (in accordance with a major aspect) an apparatus. The apparatus includes and is not limited to (comprises) a tissue-spreader assembly. The tissue-spreader assembly is configured to be selectively inserted into a patient having a first biological tissue and a second biological tissue positioned proximate to the first biological tissue. The tissue-spreader assembly is also configured to be maneuvered proximate to the second biological tissue. The tissue-spreader assembly is also configured to selectively engage, at least in part, an area of the second biological tissue without engaging the first biological tissue after the tissue-spreader assembly, in use, is maneuvered proximate to the second biological tissue. The tissue-spreader assembly is also configured to selectively spread, at least in part, the area of the second biological tissue, and maintain the area of the second biological tissue in a spread-apart condition (this is done, preferably, after the tissue-spreader assembly, in use, selectively engages, at least in part, the area of the second biological tissue without engaging the first biological tissue).


To mitigate, at least in part, at least one problem associated with the existing technology, there is provided (in accordance with a major aspect) a method. The method is for selectively spreading a second biological tissue positioned proximate to a first biological tissue of a patient. The method includes and is not limited to (comprises) selectively inserting a tissue-spreader assembly into the patient. The method also includes maneuvering the tissue-spreader assembly to a position located proximate to the second biological tissue. The method also includes using the tissue-spreader assembly to selectively engage, at least in part, an area of the second biological tissue without engaging the first biological tissue after the tissue-spreader assembly, in use, is maneuvered proximate to the second biological tissue. The method also includes using the tissue-spreader assembly to selectively spread, at least in part, the area of the second biological tissue, and maintain the area of the second biological tissue in a spread-apart condition (this is done, preferably, after the tissue-spreader assembly, in use, selectively engages, at least in part, the area of the second biological tissue without engaging the first biological tissue).


Other aspects and features of the non-limiting embodiments may now become apparent to those skilled in the art upon review of the following detailed description of the non-limiting embodiments with the accompanying drawings. This Summary is provided to introduce concepts in simplified form that are further described below in the Detailed Description. This Summary is not intended to identify potentially key features or possible essential features of the disclosed subject matter, and is not intended to describe each disclosed embodiment or every implementation of the disclosed subject matter. Many other novel advantages, features, and relationships will become apparent as this description proceeds. The figures and the description that follow more particularly exemplify illustrative embodiments.





BRIEF DESCRIPTION OF THE DRAWINGS

The non-limiting embodiments may be more fully appreciated by reference to the following detailed description of the non-limiting embodiments when taken in conjunction with the accompanying drawings, in which:



FIG. 1, FIG. 2 and FIG. 3 depict side perspective views (FIG. 1 and FIG. 2) and a cross-sectional view (FIG. 3) of embodiments of a tissue-spreader assembly; and



FIG. 4 and FIG. 5 depict side perspective views of embodiments of the tissue-spreader assembly of FIG. 1; and



FIG. 6 to FIG. 13 depict side schematic views of embodiments of the tissue-spreader assembly of FIG. 1; and



FIG. 14 depicts a side perspective view of an embodiment of the tissue-spreader assembly of FIG. 1; and



FIG. 15 depicts a side perspective view of an embodiment of the tissue-spreader assembly of FIG. 1.





The drawings are not necessarily to scale and may be illustrated by phantom lines, diagrammatic representations, and fragmentary views. In certain instances, details unnecessary for an understanding of the embodiments (and/or details that render other details difficult to perceive) may have been omitted. Corresponding reference characters indicate corresponding components throughout the several figures of the drawings. Elements in the several figures are illustrated for simplicity and clarity and have not been drawn to scale. The dimensions of some of the elements in the figures may be emphasized relative to other elements for facilitating an understanding of the various disclosed embodiments. In addition, common, and well-understood, elements that are useful in commercially feasible embodiments are often not depicted to provide a less obstructed view of the embodiments of the present disclosure.












LISTING OF REFERENCE NUMERALS USED IN THE DRAWINGS
















first tube 100
second tube lumen 202


radial-offset distance 101
first tube lumen 208


prongs (102A, 102B, 102C, 102D)
tissue-spreader assembly 300


bowed portions
guide path 302


(104A, 104B, 104C, 104D)
first biological tissue 900


retraction direction 103
patient 903


prong-movement direction 105
exposed surface 901


distal tip section 106
second biological tissue 902


second tube 108
puncture device 904


spaced-apart support grooves
distal puncture tip 906


(110A, 110D)
ancillary device 907


tube portal 112
exposed passageway 908









DETAILED DESCRIPTION OF THE NON-LIMITING EMBODIMENT(S)

The following detailed description is merely exemplary and is not intended to limit the described embodiments or the application and uses of the described embodiments. As used, the word “exemplary” or “illustrative” means “serving as an example, instance, or illustration.” Any implementation described as “exemplary” or “illustrative” is not necessarily to be construed as preferred or advantageous over other implementations. All of the implementations described below are exemplary implementations provided to enable persons skilled in the art to make or use the embodiments of the disclosure and are not intended to limit the scope of the disclosure. The scope of the disclosure is defined by the claims. For the description, the terms “upper,” “lower,” “left,” “rear,” “right,” “front,” “vertical,” “horizontal,” and derivatives thereof shall relate to the examples as oriented in the drawings. There is no intention to be bound by any expressed or implied theory in the preceding Technical Field, Background, Summary, or the following detailed description. It is also to be understood that the devices and processes illustrated in the attached drawings, and described in the following specification, are exemplary embodiments (examples), aspects and/or concepts defined in the appended claims. Hence, dimensions and other physical characteristics relating to the embodiments disclosed are not to be considered as limiting, unless the claims expressly state otherwise. It is understood that the phrase “at least one” is equivalent to “a”. The aspects (examples, alterations, modifications, options, variations, embodiments and any equivalent thereof) are described regarding the drawings. It should be understood that the disclosure is limited to the subject matter provided by the claims, and that the disclosure is not limited to the particular aspects depicted and described. It will be appreciated that the scope of the meaning of a device configured to be coupled to an item (that is, to be connected to, to interact with the item, etc.) is to be interpreted as the device being configured to be coupled to the item, either directly or indirectly. Therefore, “configured to” may include the meaning “either directly or indirectly” unless specifically stated otherwise.



FIG. 1, FIG. 2 and FIG. 3 depict side perspective views (FIG. 1 and FIG. 2) and a cross-sectional view (FIG. 3) of embodiments of a tissue-spreader assembly 300.


Referring to the embodiment as depicted in FIG. 1, the tissue-spreader assembly 300 is depicted in an undeployed condition. The undeployed condition may be called a non-spread condition, a contained position, a storage condition, etc., and any equivalent thereof. The tissue-spreader assembly 300 is configured to be inserted into a confined space defined by a living body (the patient), etc.


Referring to the embodiment as depicted in FIG. 2, the tissue-spreader assembly 300 is depicted in the deployed condition (also called the spread configuration, etc., and any equivalent thereof). The tissue-spreader assembly 300 includes, preferably, components having biocompatible material properties suitable for sufficient and/or safe performance (such as dielectric strength, thermal, insulation, corrosion, water and/or heat resistance, etc.), for compliance with industrial and regulatory safety standards (or compatible for medical usage), etc. Reference may be made to the following publication for consideration in the selection of a suitable material: Plastics in Medical Devices: Properties, Requirements, and Applications; 2nd Edition; author: Vinny R. Sastri; hardcover ISBN: 9781455732012; published: 21 Nov. 2013; publisher: Amsterdam [Pays-Bas]: Elsevier/William Andrew, [2014].


Referring to the embodiment as depicted in FIG. 1, the tissue-spreader assembly 300 includes a first tube 100 (also called an outer tube) and a second tube 108 (also called an inner tube). The first tube 100 and the second tube 108 are configured to interact (cooperate) with each other. The second tube 108 is configured to be received within (and along) a longitudinal length of the first tube 100. The first tube 100 and the second tube 108 are configured to be coaxially aligned (and movably slidable) with each other once the second tube 108 is received within, and along, the longitudinal length of the first tube 100. Preferably, the second tube 108 is slidably receivable (movable) along the longitudinal axis extending along the first tube lumen 208 of the first tube 100 by application of a movement force, etc., by the user, either directly or indirectly. The first tube 100 may be called a containing sheath, and any equivalent thereof. The first tube 100 defines the first tube lumen 208 configured to slidably receive the second tube 108 (therein and therealong). The second tube 108 is configured to be received within the first tube lumen 208 of the first tube 100. The second tube 108 has, preferably, a sufficiently rigid property (and/or is substantially not flexible) within an acceptable degree of tolerance, so that the second tube 108 may be pushed through tissue (if so required). The second tube 108 defines the second tube lumen 202 (extending along a longitudinal length of the second tube 108). The distal tip section 106 extends (depends) from an end portion (distal portion) of the second tube 108. The distal tip section 106 also defines (at least in part) the second tube lumen 202. The distal tip section 106 forms (provides), preferably, an elongated cone section (a frustoconical shape, a cone formation) that extends from the distal portion of the second tube 108 (to improve the ability of insertion of the second tube 108 into tissue, if so required).


Referring to the embodiment as depicted in FIG. 1, the biased bowed portions (104A, 104B, 104C, 104D) are positioned between the first tube 100 and the second tube 108 once (after) the tissue-spreader assembly 300 is placed in the undeployed condition, as depicted in FIG. 1. In the undeployed condition, the first tube 100 is configured to substantially cover the second tube 108 so that the biased bowed portions (104A, 104B, 104C, 104D) may remain covered by the first tube 100. The first tube 100 is positioned over top of (configured to selectively cover) the biased bowed portions (104A, 104B, 104C, 104D) in the undeployed condition (as depicted in FIG. 1). The biased bowed portions (104A, 104B, 104C, 104D) face (contact, are positioned proximate to) the inner surface (of the first tube 100) forming the first tube lumen 208 (of the first tube 100) in the undeployed condition. The biased bowed portions (104A, 104B, 104C, 104D) face (contact, are positioned proximate to) the outer surface of the second tube 108 in the undeployed condition. The biased bowed portions (104A, 104B, 104C, 104D) may include bowed metal pieces, spring-biased components, biased portions, etc., and any equivalent thereof. This arrangement (as depicted in FIG. 1) compresses the biased bowed portions (104A, 104B, 104C, 104D), and forces the biased bowed portions (104A, 104B, 104C, 104D) to run parallel (to become aligned in a parallel relationship) to the second tube 108 in the undeployed condition (as depicted in FIG. 1).


Referring to the embodiment as depicted in FIG. 1, the biased bowed portions (104A, 104B, 104C, 104D) are configured to be positioned between the first tube 100 and the second tube 108 after the tissue-spreader assembly 300 is placed in an undeployed condition. The biased bowed portions (104A, 104B, 104C, 104D) are also configured to be compressed after the tissue-spreader assembly 300 is placed in an undeployed condition (as depicted in FIG. 1). Once the first tube 100 is moved relative to the second tube 108, the biased bowed portions (104A, 104B, 104C, 104D) are released and may become decompressed, after the tissue-spreader assembly 300 is placed in a deployed condition (as depicted in FIG. 2).


Referring to the embodiment as depicted in FIG. 1, the prongs (102A, 102B, 102C, 102D) are movable between the undeployed condition (as depicted in FIG. 1) and the deployed condition (as depicted in FIG. 2). The prongs (102A, 102B, 102C, 102D) are positioned in the undeployed condition, as depicted in FIG. 1. The prongs (102A, 102B, 102C, 102D) extend, respectively, from the biased bowed portions (104A, 104B, 104C, 104D). The prongs (102A, 102B, 102C, 102D) are configured to engage, at least in part, the area of the second biological tissue 902 (as depicted in FIG. 4 and FIG. 5, etc.). The prongs (102A, 102B, 102C, 102D) may include a metal alloy, etc., and any equivalent thereof. The prongs (102A, 102B, 102C, 102D) may include grippers, thin metal grippers, etc., and any equivalent thereof.


Preferably, the prongs (102A, 102B, 102C, 102D) include hollow tubes with open portals configured to face axially away from the biased bowed portions (104A, 104B, 104C, 104D). The open portals are also configured to be embedded (engaged), at least in part, into the second biological tissue 902 (as depicted in FIG. 4 and/or FIG. 5). The prongs (102A, 102B, 102C, 102D) include, preferably, hollow tubes with open portals configured to face the second biological tissue 902 (as depicted in FIG. 4 and/or FIG. 5) once the tissue-spreader assembly 300 is positioned proximate to the second biological tissue 902. It will be appreciated that the dashed lined prongs (102A′, 102B′) demonstrate the positions of the prongs (102A, 102B), of FIG. 1, in their respective deployed conditions, while FIG. 2 depicts the prongs (102A, 102B) positioned in their respective deployed conditions, etc. The prongs (102A, 102B) are configured to be movable (laterally movable away from the longitudinal axis extending through the first tube 100) along the prong-movement direction 105 (between their respective deployed conditions, as depicted in FIG. 2, and their respective undeployed conditions as depicted in FIG. 1). The prongs (102A, 102B, 102C, 102D) extend past the distal end of the second tube 108 (as depicted in FIG. 1 and in FIG. 2) whether they are deployed as depicted in FIG. 1 or FIG. 2. The prongs (102A, 102B, 102C, 102D) extend past a distal end of the second tube 108 once (after) the prongs (102A, 102B, 102C, 102D) are moved from the undeployed condition to the deployed condition. The prongs (102A, 102B, 102C, 102D) extend past the tube portal 112 of the second tube 108 (reference is made to FIG. 14 and FIG. 15). The prongs (102A, 102B, 102C, 102D) are configured to be embedded, at least in part, in the second biological tissue 902, and the second biological tissue 902 is positioned over the first biological tissue 900 (for instance, as depicted in FIG. 4 and FIG. 5).


Referring to the embodiment as depicted in FIG. 1, the prongs (102A, 102B, 102C, 102D) and/or the biased bowed portions (104A, 104B, 104C, 104D) may include a shape-memory material configured to be manipulated and/or deformed followed by a return to the original shape that the shape-memory material had been set in (prior to manipulation). Shape-memory materials (SMMs) are known and not further described in detail. Shape-memory materials are configured to recover their original shape from a significant and seemingly plastic deformation in response to a particular stimulus being applied to the shape-memory material. This is known as the shape memory effect (SME). Superelasticity (in alloys) may be observed once the shape-memory material is deformed under the presence (an application) of a stimulus force.


Referring to the embodiment as depicted in FIG. 1, the prongs (102A, 102B, 102C, 102D) and/or the biased bowed portions (104A, 104B, 104C, 104D) may include SAE (Society of Automotive Engineering) Type 304 Stainless Steel. SAE Type 304 stainless steel contains both chromium (from between about 15% to about 20%) and nickel (from between about 2% to about 10.5%) metals as the main non-iron constituents.


Referring to the embodiment as depicted in FIG. 1, an ancillary device 907 is configured to be received (at least in part) along the second tube lumen 202 of the second tube 108. The ancillary device 907 may include, for instance, a puncture device 904 configured to form a puncture through (or simply cut) biological tissue, etc. This is done, preferably, after the puncture device 904 is received along the second tube lumen 202 of the second tube 108 and is positioned accordingly. The puncture device 904 is configured to be movable along the guide path 302 (extending along a length of the second tube lumen 202 extending along, at least in part, a length of the tissue-spreader assembly 300). The puncture device 904 includes, preferably, a distal puncture tip 906 (reference is made to FIG. 9, FIG. 10 and FIG. 11). The ancillary device 907 (or the puncture device 904) is configured to be (at least in part) inserted into, and movable along, the second tube lumen 202. The second tube lumen 202 is, preferably, reinforced for (or provides) sufficient stiffness during insertion of the second tube lumen 202 into the patient (if required). The distal tip section 106 (also called the tapered distal section) is configured, preferably, for ease of insertion of the leading edge of the tissue-spreader assembly 300 through tissue, etc., if required. The prongs (102A, 102B, 102C, 102D) are configured to (positioned to) surround a circumference surface of the distal tip section 106, and extend slightly past the distal tip section 106. The first tube 100 (also called a surrounding sheath) is configured to selectively contain (cover) the prongs (102A, 102B, 102C, 102D), as depicted in FIG. 1. The first tube 100 is configured to be shifted (moved or slid) relative to the second tube 108 to facilitate releasement (biased movement, biased bowing outwards) of the prongs (102A, 102B, 102C, 102D), as depicted in FIG. 2. The ancillary device 907 and/or the puncture device 904 is/are configured to be inserted (at least in part) into the second tube lumen 202 of the second tube 108. The puncture device 904 may include sufficient rigidity for traversing through patient anatomy to gain access (such as to the heart, etc.), if so required. The puncture device 904 is configured, preferably, to prevent creation of a tissue core when traversing the patient anatomy and/or to provide a leading edge configured to facilitate easier traversal through tissue, etc., if so required. The puncture device 904 may include a stylet, a radio-frequency puncture device, etc., and any equivalent thereof. The radio-frequency puncture device may, for instance, include (and is not limited to) a radio frequency puncture device, such as the BAYLIS (TRADEMARK) POWERWIRE (REGISTERED TRADEMARK), a radio frequency guidewire manufactured by BAYLIS MEDICAL COMPANY (headquartered in Canada). The radio-frequency puncture device does not, preferably, require mechanical force to puncture tissue, but rather, may rely on the application (emission) of radio frequency energy to the tissue, which vaporizes the tissue and creates (forms) a puncture, etc., through the tissue. The radio-frequency puncture device, with precise applied timing of radio frequency energy, may be used to selectively puncture only the second biological tissue 902 but not the first biological tissue 900 (that is, while not harming or damaging the first biological tissue 900). This condition may be performed via the manipulation or use of: (A) precise pre-tenting force applied with a blunt radio-frequency puncture device (with only enough force applied to the puncture device prior to application of radio frequency energy to facilitate puncture of the second biological tissue 902 when the radio frequency energy is applied); (B) impedance readings to determine when the second biological tissue 902 has been punctured and thus application of the radio frequency energy may be stopped; and/or (C) precise timed application of the radio frequency energy (that is, the radio frequency energy may only be turned on for a period of time where the second biological tissue 902 is punctured without puncturing and/or damaging the first biological tissue 900). Impedance measurements or impedance readings (from the tissue) may indicate when the space has been formed through the second biological tissue 902 and may indicate to a user when to stop applying force to the puncture device, etc., to avoid damaging the first biological tissue 900. Ultrasound readings, from an ultrasound emitter (known and not depicted), may allow a user to determine when they have punctured the second biological tissue 902 and may indicate that the user may stop applying puncture force, etc., to avoid damaging the first biological tissue 900. A laser measuring device (known and not depicted) may be used for measuring tissue properties and determining when the space has been formed through the second biological tissue 902 (this arrangement might be used to indicate when the chosen puncture modality might cease operation).


Referring to the embodiment as depicted in FIG. 1, the first tube 100 is configured to force (move) the biased bowed portions (104A, 104B, 104C, 104D) to be pressed against the body of the second tube 108, once the first tube 100 is moved coaxially along the second tube 108. The first tube 100 is configured to compress the biased bowed portions (104A, 104B, 104C, 104D) in response to the first tube 100 being moved to cover the biased bowed portions (104A, 104B, 104C, 104D), as depicted in FIG. 1. The longitudinal length of the first tube 100 is, preferably, sufficient to cover the biased bowed portions (104A, 104B, 104C, 104D) on (at) a distal portion of the second tube 108. The first tube 100 is configured to be manipulated (moved), proximally, to selectively move (coaxially) along the second tube 108 (by the user via linkages, etc., known and not depicted). The tissue-spreader assembly 300 (or the first tube 100) is configured to operate and (in concert with the other components) facilitate the stretching of the second biological tissue 902. The first tube 100 has an inner diameter that is compatible with the outer diameter of second tube 108 and the biased bowed portions (104A, 104B, 104C, 104D) for cooperative action. The first tube 100 is configured to reduce the bow angle formed by the biased bowed portions (104A, 104B, 104C, 104D), as depicted in FIG. 2, to about, preferably, zero (0) degrees as depicted in FIG. 1; that is, the biased bowed portions (104A, 104B, 104C, 104D) become aligned substantially parallel (in a parallel relationship) with a longitudinal length of the second tube 108. The first tube 100 is configured to maneuver the prongs (102A, 102B, 102C, 102D), which extend from the biased bowed portions (104A, 104B, 104C, 104D), from the undeployed condition (as depicted in FIG. 1) to the deployed condition (as depicted in FIG. 2); this is done (preferably) once (or after) the first tube 100 is moved (retracted) away from the tube portal 112 (or the distal tip section 106) (as depicted in FIG. 2); that is once (or after) the first tube 100 is retracted proximally over (and along) the second tube 108 (as depicted in FIG. 2).


Referring to the embodiment as depicted in FIG. 1, the prongs (102A, 102B, 102C, 102D) extend from the biased bowed portions (104A, 104B, 104C, 104D). The prongs (102A, 102B, 102C, 102D) end or terminate at a location distal to the end portion of the distal tip section 106 of the second tube 108. The biased bowed portions (104A, 104B, 104C, 104D) are set to a shape that bows outwardly from the second tube 108 near the distal end of the second tube 108 (once the first tube 100 is moved, as depicted in FIG. 2). Once the first tube 100 is positioned over top of the biased bowed portions (104A, 104B, 104C, 104D), the first tube 100, in use, compresses and conforms the shape of the biased bowed portions (104A, 104B, 104C, 104D) to the outer surface of the second tube 108.


Referring to the embodiment as depicted in FIG. 2, once the first tube 100 is moved to expose (at least in part) the outer surface of the second tube 108, the biased bowed portions (104A, 104B, 104C, 104D) are able to return from their stressed condition (as depicted in FIG. 1) to their relaxed position (the biased condition, as depicted in FIG. 2), and bow outwardly from the outer surface of the second tube 108 (as depicted in FIG. 2).


Referring to the embodiments as depicted in FIG. 1, FIG. 2 and FIG. 3, there may be (for instance) a quantity of at least two (2) instances of the prongs (102A, 102B, 102C, 102D) and the biased bowed portions (104A, 104B, 104C, 104D). As depicted, there are a quantity of four (4) prongs and respective bowed portions in order to facilitate biaxial tissue stretching, which may result in a greater ability to increase application of the stress forces (stretch forces) to the second biological tissue 902 (such as, the pericardial tissue). The length of the prongs (102A, 102B, 102C, 102D) extends, preferably, past the distal end of the second tube 108. The prongs (102A, 102B, 102C, 102D) may extend, preferably, about 0.5 millimeters past the tube portal 112 of the distal tip section 106 (or of the distal end portion of the second tube 108, etc.). This arrangement may ensure that the prongs (102A, 102B, 102C, 102D) may become embedded (at least in part) to (in) the second biological tissue 902 without disturbing (or without damaging) the first biological tissue 900 (such as, the underlying myocardium), as depicted in FIG. 4 and FIG. 5.


Referring to the embodiment as depicted in FIG. 1, the biased bowed portions (104A, 104B, 104C, 104D) terminate distally at the prongs (102A, 102B, 102C, 102D). The biased bowed portions (104A, 104B, 104C, 104D) may include a stainless-steel alloy, etc., and any equivalent thereof. The dimensions of the prongs (102A, 102B, 102C, 102D) and/or the biased bowed portions (104A, 104B, 104C, 104D) may be any suitable dimension and/or configuration that is configured to engage and/or grip the tissue. It will be appreciated that the biased bowed portions (104A, 104B, 104C, 104D) are a preferred mechanism for stretching the second biological tissue 902.


Referring to the embodiment as depicted in FIG. 1, the bow angle of the biased bowed portions (104A, 104B, 104C, 104D) may be set to about 7.0 degrees, and/or about 15 millimeters (mm) from the distal end of the second tube 108 (or of the distal tip section 106). The section of the prongs (102A, 102B, 102C, 102D) may have (subtend) an angle of about 10.0 degrees in order to conform to the tapered section of the distal tip section 106 when the biased bowed portions (104A, 104B, 104C, 104D) are positioned in the contained position (as depicted in FIG. 1). These values may be changed depending on configurations and/or arrangements of the components, etc. The biased bowed portions (104A, 104B, 104C, 104D) are configured to be moved away from the outer surface of the second tube 108 (once they are released, as depicted in FIG. 2).


Referring to the embodiment as depicted in FIG. 1, the second tube 108 defines the second tube lumen 202 configured to receive (for insertion of) the ancillary device 907. The second tube 108 includes, preferably, HDPE material (high-density polyethylene) and any equivalent thereof. The second tube 108 may have a longitudinal length of about six (6.0) inches. The second tube lumen 202 (of the second tube 108) may have a diameter of about 0.035 to about 0.039 inches. The second tube 108 may have an outer diameter of about 8.0 Fr to about 8.5 Fr. The French scale or French gauge system is used to measure the size of a catheter, and is most often abbreviated as Fr. The second tube 108 includes, preferably, a reinforced stainless steel hypotube. The distal tip section 106 (the distal section of the second tube 108) is tapered to facilitate ease of insertion into, and along, the cavities and/or tissues of the patient. The second tube 108 is configured to provide an anchor for the biased bowed portions (104A, 104B, 104C, 104D) and a fixed point from which to spread tissue (therefrom). The material of the second tube 108 may be any material that provides sufficient rigidity and/or is biocompatible. The functional length of the second tube 108 may be any length, such as the length needed for percutaneous access to the heart, etc. The inner diameter of the second tube 108 may be any size, but the specified diameter is sufficient to provide compatibility for the ancillary device 907. The outer diameter of the second tube 108 may be any size. The second tube 108 may include a reinforced stainless steel hypotube that may be provided for greater device stiffness when present for traversing through patient anatomy, such as when trying to access the heart percutaneously. The distal tip section 106 does not need to be tapered for the purposes of spreading tissue (such as the pericardial tissue). The distal tip section 106 is a preferred feature that enhances usability, and the distal tip section 106 is not a necessary feature.


Referring to the embodiment as depicted in FIG. 2, the biased bowed portions (104A, 104B, 104C, 104D) are configured to be resiliently biased. The first tube 100 is moved proximally (away from the distal tip portion of the second tube 108). Movement of the first tube 100 along the retraction direction 103 exposes the biased bowed portions (104A, 104B, 104C, 104D) and, in response, the biased bowed portions (104A, 104B, 104C, 104D) resiliently move (may move to a biased condition) to a relaxed configuration (as depicted in FIG. 2), also called a bent configuration. Once the biased bowed portions (104A, 104B, 104C, 104D) resiliently move to their respective relaxed configurations, the prongs (102A, 102B, 102C, 102D) become spread away, laterally, from the distal tip (the tube portal 112) of the second tube 108. Between the end portions of the prongs (102A, 102B, 102C, 102D) and the distal tip (the tube portal 112) of the second tube 108, the radial-offset distance 101 is maintained.


Referring to the embodiment as depicted in FIG. 2, positioned on the outer surface of the second tube 108 are spaced-apart support grooves (110A, 110D), also depicted in FIG. 5 and FIG. 15. The spaced-apart support grooves (110A, 110D) respectively correspond to bowed portions (104A, 104B, 104C, 104D). The spaced-apart support grooves (110A, 110D) are configured to respectively selectively receive, and/or support, the biased bowed portions (104A, 104B, 104C, 104D); this is done, preferably, after the support bowed portions (104A, 104B, 104C, 104D are positioned in the undeployed condition, as depicted in FIG. 1.


Referring to the embodiment as depicted in FIG. 3, the cross-sectional view of the tissue-spreader assembly 300 is depicted. The cross-sectional view is taken along the cross-sectional line A-A of FIG. 2.



FIG. 4 and FIG. 5 depict side perspective views of embodiments of the tissue-spreader assembly 300 of FIG. 1.


Referring to the embodiment as depicted in FIG. 4, the tissue-spreader assembly 300 is configured to decrease the input force required to puncture the second biological tissue 902 (such as, the pericardium) relative to the first biological tissue 900 (such as, the myocardium). The tissue-spreader assembly 300 is configured to spread a section (an area, a zone) of the second biological tissue 902, while the second biological tissue 902 is positioned over (adjacent to) the first biological tissue 900. Tissue puncture may be achieved by applying stress to the second biological tissue 902 until the second biological tissue 902 fails (rips, etc.). The stress required to create a puncture through the second biological tissue 902 might be thought of as a failure threshold of the second biological tissue 902. By applying a tensile force to a region of the second biological tissue 902 using the tissue-spreader assembly 300, the stress in that localized region of the second biological tissue 902 may be increased. Thus, the additional stress input required (to be applied) to achieve tissue failure (puncture) is decreased. This is analogous to popping a balloon; the more the balloon is inflated, the greater the material of the balloon is stressed, which means it is easier to pop (puncture) the balloon (the second biological tissue 902).


Referring to the embodiment as depicted in FIG. 4, the tissue-spreader assembly 300 is configured to generate (impart) stress in (to) the second biological tissue 902 (such as the pericardium layer); this is preferably done prior to an attempt to puncture the second biological tissue 902. Once the stretching stress is applied, by the tissue-spreader assembly 300 to the second biological tissue 902, it is relatively easier to form a puncture through the second biological tissue 902 (pericardium layer) relative to the first biological tissue 900 (the myocardium layer) when a user uses the puncture device 904. The tissue-spreader assembly 300 decreases, at least in part, the chance of a user inadvertently puncturing the first biological tissue 900 (the myocardium) since it becomes easier to puncture the second biological tissue 902. For instance, the tissue-spreader assembly 300 may be utilized to facilitate the puncturing of the pericardium layer for gaining epicardial access, etc., for a heart procedure.


Referring to the embodiment as depicted in FIG. 4, a user positions the tissue-spreader assembly 300 on (proximate to) the second biological tissue 902 (the pericardium layer) with the first tube 100 in position against the second tube 108, and the prongs (102A, 102B, 102C, 102D) are positioned to engage the second biological tissue 902. The prongs (102A, 102B, 102C, 102D) may engage (embed to, or grip) the second biological tissue 902 (that is, the pericardium layer) without disturbing or gripping the first biological tissue 900 (that is, the underlying myocardium layer). The user pulls back the first tube 100 relative to the second tube 108 which exposes the biased bowed portions (104A, 104B, 104C, 104D). This releasing action causes the biased bowed portions (104A, 104B, 104C, 104D) to return to their relaxed (bowed) configuration, and to move away from the second tube 108. This action or movement causes the prongs (102A, 102B, 102C, 102D) to do the same, which causes the second biological tissue 902 (the pericardium layer) to stretch relative to the first biological tissue 900 (the underlying myocardium layer), as depicted in FIG. 5.


Referring to the embodiment as depicted in FIG. 4, the tissue-spreader assembly 300 is depicted in the undeployed condition (the contained position). The prongs (102A, 102B, 102C, 102D) are engaged with (inserted, at least in part, into) a section (an area) of the second biological tissue 902. The second biological tissue 902 includes, preferably, pericardial tissue of the heart of the patient. For instance, the pericardial tissue is a relatively thin membrane forming a sack around the heart muscle (similar to the fascia that wrap around a muscle). The second biological tissue 902 may cover the first biological tissue 900. The first biological tissue 900 includes, preferably, the myocardium (myocardium layer) of the heart of the patient. The myocardium is the contractile component of the heart. The prongs (102A, 102B, 102C, 102D) are extended and only embed themselves, at least in part, into the second biological tissue 902, and the prongs (102A, 102B, 102C, 102D) do not contact (extend into) the first biological tissue 900.


Referring to the embodiment as depicted in FIG. 4, the tissue-spreader assembly 300 in a contained position inserted into a section of the biological tissue (such as the pericardium layer). The prongs (102A, 102B, 102C, 102D) only embed themselves into the biological tissue 902 (the pericardium), but do not come into contact with the first biological tissue 900 (the underlying myocardium).


Referring to the embodiment as depicted in FIG. 5, the tissue-spreader assembly 300 is placed in the deployed condition (the spread position). The prongs (102A, 102B, 102C, 102D) have moved laterally and have stretched the second biological tissue 902 (the pericardial tissue) such that they are embedded into but not embedded (or engaged with) the first biological tissue 900 (that is, the underlying myocardium). The prongs (102A, 102B, 102C, 102D) are configured to increase the stress in the stretched section of the second biological tissue 902 (the pericardial tissue) which lowers the required force to puncture the second biological tissue 902.


Referring to the embodiments as depicted in FIG. 4 and FIG. 5, the tissue-spreader assembly 300 is configured to be selectively inserted into the patient 903 having the first biological tissue 900 and the second biological tissue 902 positioned proximate to the first biological tissue 900. The tissue-spreader assembly 300 is also configured to be maneuvered (and positioned) proximate to the second biological tissue 902. The tissue-spreader assembly 300 is also configured to selectively engage (contact), at least in part, an area of the second biological tissue 902 (but) without engaging (contacting) the first biological tissue 900 after the tissue-spreader assembly 300, in use, is maneuvered (and positioned) proximate to the second biological tissue 902. The tissue-spreader assembly 300 is also configured to selectively spread, at least in part, the area of the second biological tissue 902, and maintain the area of the second biological tissue 902 in a spread-apart condition; this is done, preferably, after the tissue-spreader assembly 300, in use, selectively engages (contacts), at least in part, the area of the second biological tissue 902 (but) without engaging (contacting) the first biological tissue 900. The definition of selectively spread includes stretching the second biological tissue 902 in any manner, such as a uniaxial manner, a biaxial manner and/or an omni-axial manner, to increase the stress so that the second biological tissue 902 may easily separate from the first biological tissue 900. The definition of selectively engage includes any manner of gripping, selecting, embedding an area, or a region, of the second biological tissue 902 separately from the first biological tissue 900.


Referring to the embodiments as depicted in FIG. 4 and FIG. 5, the second biological tissue 902 is positioned to be in contact with the first biological tissue 900.


Referring to the embodiments as depicted in FIG. 4 and FIG. 5, the second biological tissue 902 is positioned over the first biological tissue 900.


Referring to the embodiments as depicted in FIG. 4 and FIG. 5, the tissue-spreader assembly 300 is also configured to selectively disengage from the area of the second biological tissue 902.


Referring to the embodiments as depicted in FIG. 4 and FIG. 5, the tissue-spreader assembly 300 is also configured to selectively permit the area of the second biological tissue 902 to become relaxed from the spread-apart condition.


Referring to the embodiments as depicted in FIG. 4 and FIG. 5, the tissue-spreader assembly 300 is also configured to selectively disengage from the area of the second biological tissue 902.


Referring to the embodiments as depicted in FIG. 4 and FIG. 5, the tissue-spreader assembly 300 includes prongs (102A, 102B, 102C, 102D) configured to selectively engage (contact), at least in part, the area of the second biological tissue 902. The prongs (102A, 102B, 102C, 102D) are also configured to selectively spread, at least in part, the area of the second biological tissue 902 after the prongs (102A, 102B, 102C, 102D) selectively engage (contact), at least in part, the area of a second biological tissue 902.


Referring to the embodiments as depicted in FIG. 4 and FIG. 5, the tissue-spreader assembly 300 is also configured to provide a guide path 302 configured to guide, at least in part, an ancillary device 907 toward the area of the second biological tissue 902 while the area of the second biological tissue 902 remains spread apart by the tissue-spreader assembly 300 and while the first biological tissue 900 remains unengaged with the tissue-spreader assembly 300.


Referring to the embodiments as depicted in FIG. 4 and FIG. 5, the tissue-spreader assembly 300 is also configured to selectively disengage from the area of the second biological tissue 902 after the ancillary device 907 has completed application of treatment to the area of the second biological tissue 902.


Referring to the embodiments as depicted in FIG. 4 and FIG. 5, the ancillary device 907 is configured to treat the area of the second biological tissue 902 while the area of the second biological tissue 902 remains spread apart by the tissue-spreader assembly 300.


Referring to the embodiments as depicted in FIG. 4 and FIG. 5, the ancillary device 907 is configured to contact, at least in part, the area of the second biological tissue 902 (but) without contacting the first biological tissue 900 after the area of the second biological tissue 902 is spread apart by the tissue-spreader assembly 300.


Referring to the embodiments as depicted in FIG. 4 and FIG. 5, the ancillary device 907 includes a puncture device 904 configured to impart a puncture force sufficient for puncturing the second biological tissue 902 (but) without puncturing the first biological tissue 900 after the area of the second biological tissue 902 is selectively spread apart by the tissue-spreader assembly 300.


Referring to the embodiments as depicted in FIG. 4 and FIG. 5, there is depicted a method of selectively spreading the second biological tissue 902 positioned proximate to the first biological tissue 900 of the patient 903. The method includes selectively inserting a tissue-spreader assembly 300 into the patient 903. The method also includes maneuvering (and positioning) the tissue-spreader assembly 300 to a position located proximate to the second biological tissue 902. The method also includes using the tissue-spreader assembly 300 to selectively engage (contact), at least in part, an area of the second biological tissue 902 (but) without engaging (contacting) the first biological tissue 900 after the tissue-spreader assembly 300, in use, is maneuvered (and positioned) proximate to the second biological tissue 902. The method also includes using the tissue-spreader assembly 300 to selectively spread, at least in part, the area of the second biological tissue 902, and maintain the area of the second biological tissue 902 in a spread-apart condition after the tissue-spreader assembly 300, in use, selectively engages (contacts), at least in part, the area of the second biological tissue 902 (but) without engaging (contacting) the first biological tissue 900. The method may be utilized when the second biological tissue 902 is positioned to be in contact with the first biological tissue 900. The method may be utilized when the second biological tissue 902 is positioned over the first biological tissue 900.



FIG. 6 to FIG. 13 depict side schematic views of embodiments of the tissue-spreader assembly 300 of FIG. 1.


Referring to the embodiments of FIG. 6 to FIG. 13, the prongs (102A, 102D) and the ancillary device 907 (or the distal puncture tip 906 of the puncture device 904) are utilized to puncture the second biological tissue 902 (such as the pericardium layer of the heart, etc., to facilitate epicardial access). The user positions the distal end of the tissue-spreader assembly 300 proximate to the second biological tissue 902. The prongs (102A, 102D) are utilized to become embedded, or to grip, the second biological tissue 902. The prongs (102A, 102D) are moved from the undeployed condition (as shown in FIG. 1) to the deployed condition (as shown in FIG. 2). For instance, the user may shift the first tube 100 proximally on the tissue-spreader assembly 300 causing the biased bowed portions (104A, 104B, 104C, 104D) along the second tube 108 to become exposed, etc. The biased bowed portions (104A, 104D) return to their relaxed configuration (as depicted in FIG. 2, angled outwards from the second tube 108) and cause the prongs (102A, 102D) to move laterally relative to the distal tip of the tissue-spreader assembly 300 (or of the second tube 108), stretching the second biological tissue 902 relative to the first biological tissue 900 (such as the myocardial tissue, etc.). The ancillary device 907 (or the distal puncture tip 906 of the puncture device 904) is delivered, via the tissue-spreader assembly 300 (such as through the second tube lumen 202 of the second tube 108), and is used to puncture the second biological tissue 902. The puncture force required may be relatively lower than what may be required without utilization of the tissue-spreader assembly 300 given the increased stress imposed to (on) the second biological tissue 902 as a result of the stretching applied by the tissue-spreader assembly 300, such as by the prongs (102A, 102D), etc.


Referring to the embodiment as depicted in FIG. 6, the prongs (102A, 102D) of the tissue-spreader assembly 300 are moved toward the second biological tissue 902 (from the undeployed condition as depicted in FIG. 1 to the deployed condition). It will be appreciated that FIG. 7 to FIG. 12 depict the tissue-spreader assembly 300 in the various states of the deployed condition. The first biological tissue 900 is positioned to be in contact with (positioned proximate to) the second biological tissue 902.


Referring to the embodiment as depicted in FIG. 7, the prongs (102A, 102D) of the tissue-spreader assembly 300 engage (securely engage, contact) the second biological tissue 902. The prongs (102A, 102D) are spread apart while the prongs (102A, 102D) remain engaged (securely engaged) with the second biological tissue 902. The first biological tissue 900 is, preferably, undamaged by the movements of the prongs (102A, 102D).


Referring to the embodiment as depicted in FIG. 8, the prongs (102A, 102D) of the tissue-spreader assembly 300 are maintained in a wider spaced apart condition while the prongs (102A, 102D) continue to engage the second biological tissue 902. The second biological tissue 902 becomes thinner (stretched out) while the prongs (102A, 102D) continue to engage the second biological tissue 902. The prongs (102A, 102D) impart, to the second biological tissue 902, stretching forces while the prongs (102A, 102D) continue to engage the second biological tissue 902. The first biological tissue 900 remains, preferably, unstressed by the movements of the prongs (102A, 102D).


Referring to the embodiment as depicted in FIG. 9, the ancillary device 907 (or the distal puncture tip 906 of the puncture device 904) is moved toward the second biological tissue 902, while the second biological tissue 902 is maintained in a spread condition by the prongs (102A, 102D) of the tissue-spreader assembly 300. The prongs (102A, 102D) of the tissue-spreader assembly 300 impart, and maintain, stretching forces to the second biological tissue 902, while the ancillary device 907 (or the distal puncture tip 906 of the puncture device 904) is moved toward the second biological tissue 902 so that the ancillary device 907 may puncture the second biological tissue 902 without puncturing (damaging) the first biological tissue 900.


Referring to the embodiment as depicted in FIG. 10, the ancillary device 907 (or the distal puncture tip 906 of the puncture device 904) is moved just enough so that the ancillary device 907 manages to simply pierce (puncture) the second biological tissue 902. The second biological tissue 902 is maintained in a stretched condition by the prongs (102A, 102D) of the tissue-spreader assembly 300. The stretch forces, which are set-up in the second biological tissue 902 by the prongs (102A, 102D), become free to form (create) the exposed passageway 908 extending through the second biological tissue 902, thereby revealing the exposed surface 901 of the first biological tissue 900. The second biological tissue 902 is, preferably, damaged by the movements (operations) of the ancillary device 907 (or the distal puncture tip 906 of the puncture device 904). The first biological tissue 900 is, preferably, undamaged by the movements (operations) of the ancillary device 907 (or the distal puncture tip 906 of the puncture device 904).


Referring to the embodiment as depicted in FIG. 11, the ancillary device 907 (or the distal puncture tip 906 of the puncture device 904) is retracted away from the second biological tissue 902, while the prongs (102A, 102D) of the tissue-spreader assembly 300 are maintained in engaged contact with the second biological tissue 902. The first biological tissue 900 is, preferably, undamaged by the movements of the ancillary device 907 (or the distal puncture tip 906 of the puncture device 904). The ancillary device 907 (or the distal puncture tip 906 of the puncture device 904) has pierced (punctured) the second biological tissue 902, and the stresses set up in the second biological tissue 902 have formed the exposed passageway 908 extending through the second biological tissue 902, thereby revealing the exposed surface 901 of the first biological tissue 900.


Referring to the embodiment as depicted in FIG. 12, the prongs (102A, 102D) of the tissue-spreader assembly 300 are moved (translated) toward each other along the prong-movement direction 105. The second biological tissue 902 regains its normal (unstressed) condition or thickness after the prongs (102A, 102D) are moved (translated) toward each other. The first biological tissue 900 remains, preferably, undamaged by the movements of the prongs (102A, 102D). The second biological tissue 902 defines the exposed passageway 908 (a tear, etc.) that extends through the second biological tissue 902, thereby revealing the exposed surface 901 of the first biological tissue 900. The size of the exposed passageway 908 may become relatively smaller (compared to the size depicted in FIG. 11) after the prongs (102A, 102D) are moved (translated) toward each other.


Referring to the embodiment as depicted in FIG. 13, the prongs (102A, 102D) of the tissue-spreader assembly 300 are moved (translated) away from the second biological tissue 902 (from the deployed condition as depicted in FIG. 2 toward the undeployed condition as depicted in FIG. 1). The second biological tissue 902 regains a relaxed condition, unstressed by the prongs (102A, 102D). The second biological tissue 902 has returned to (or regained) its normal thickness, similar to the thickness prior to usage (application) of the prongs (102A, 102D). The first biological tissue 900 is, preferably, not damaged by the movements of the prongs (102A, 102D) and/or the ancillary device 907 (or the puncture device 904, etc.). The second biological tissue 902 defines the exposed passageway 908 formed by the usage of the prongs (102A, 102D) and/or the ancillary device 907 (or the puncture device 904, etc.). The exposed passageway 908 extends through the thickness of the second biological tissue 902. The exposed surface 901 of the first biological tissue 900 is now ready to be accessed by a treatment device and/or a procedure (not depicted and not described).



FIG. 14 depicts a side perspective view of an embodiment of the tissue-spreader assembly 300 of FIG. 1.


Referring to the embodiment as depicted in FIG. 14, the tissue-spreader assembly 300 is placed in the undeployed condition (the contained position). The second tube lumen 202 of the second tube 108 is configured to receive the ancillary device 907, etc. The second tube 108 defines the tube portal 112, from which the ancillary device 907 may be selectively extended therefrom, etc.



FIG. 15 depicts a side perspective view of an embodiment of the tissue-spreader assembly 300 of FIG. 1.


Referring to the embodiment as depicted in FIG. 15, the tissue-spreader assembly 300 is depicted in the deployed condition (the spread configuration).


The following is offered as further description of the embodiments, in which any one or more of any technical feature (described in the detailed description, the summary and the claims) may be combinable with any other one or more of any technical feature (described in the detailed description, the summary and the claims). It is understood that each claim in the claims section is an open-ended claim unless stated otherwise. Unless otherwise specified, relational terms used in these specifications should be construed to include certain tolerances that the person skilled in the art would recognize as providing equivalent functionality. By way of example, the term perpendicular is not necessarily limited to 90.0 degrees and may include a variation thereof that the person skilled in the art would recognize as providing equivalent functionality for the purposes described for the relevant member or element. Terms such as “about” and “substantially”, in the context of configuration, relate generally to disposition, location, or configuration that are either exact or sufficiently close to the location, disposition, or configuration of the relevant element to preserve operability of the element within the disclosure which does not materially modify the disclosure. Similarly, unless specifically made clear from its context, numerical values should be construed to include certain tolerances that the person skilled in the art would recognize as having negligible importance as they do not materially change the operability of the disclosure. It will be appreciated that the description and/or drawings identify and describe embodiments of the apparatus (either explicitly or inherently). The apparatus may include any suitable combination and/or permutation of the technical features as identified in the detailed description, as may be required and/or desired to suit a particular technical purpose and/or technical function. It will be appreciated that, where possible and suitable, any one or more of the technical features of the apparatus may be combined with any other one or more of the technical features of the apparatus (in any combination and/or permutation). It will be appreciated that persons skilled in the art would know that the technical features of each embodiment may be deployed (where possible) in other embodiments even if not expressly stated as such above. It will be appreciated that persons skilled in the art would know that other options may be possible for the configuration of the components of the apparatus to adjust to manufacturing requirements and still remain within the scope as described in at least one or more of the claims. This written description provides embodiments, including the best mode, and also enables the person skilled in the art to make and use the embodiments. The patentable scope may be defined by the claims. The written description and/or drawings may help to understand the scope of the claims. It is believed that all the crucial aspects of the disclosed subject matter have been provided in this document. It is understood, for this document, that the word “includes” is equivalent to the word “comprising” in that both words are used to signify an open-ended listing of assemblies, components, parts, etc. The term “comprising”, which is synonymous with the terms “including,” “containing,” or “characterized by,” is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. Comprising (comprised of) is an “open” phrase and allows coverage of technologies that employ additional, unrecited elements. When used in a claim, the word “comprising” is the transitory verb (transitional term) that separates the preamble of the claim from the technical features of the disclosure. The foregoing has outlined the non-limiting embodiments (examples). The description is made for non-limiting embodiments (examples). It is understood that the non-limiting embodiments are merely illustrative as examples.

Claims
  • 1. An apparatus, comprising: a tissue-spreader assembly configured to be selectively inserted into a patient having a first biological tissue and a second biological tissue being positioned over the first biological tissue, and to be maneuvered proximate to the second biological tissue; andthe tissue-spreader assembly further configured to selectively engage, at least in part, an area of the second biological tissue without engaging the first biological tissue after the tissue-spreader assembly, in use, is maneuvered proximate to the second biological tissue; andthe tissue-spreader assembly also configured to selectively spread, at least in part, the area of the second biological tissue, and maintain the area of the second biological tissue in a spread-apart condition after the tissue-spreader assembly, in use, selectively engages, at least in part, the area of the second biological tissue without engaging the first biological tissue; andthe tissue-spreader assembly also configured to provide a guide path for an ancillary device.
  • 2. The apparatus of claim 1, wherein: the tissue-spreader assembly includes: prongs configured to selectively engage, at least in part, the area of the second biological tissue; andthe prongs also configured to selectively spread, at least in part, the area of the second biological tissue after the prongs selectively engage, at least in part, the area of the second biological tissue.
  • 3. The apparatus of claim 1, wherein: the tissue-spreader assembly includes: a first tube; anda second tube configured to be received within, and along, a longitudinal length of the first tube; andthe first tube and the second tube being coaxially aligned with each other after the second tube is received within, and along, the longitudinal length of the first tube.
  • 4. The apparatus of claim 1, wherein: the tissue-spreader assembly includes: prongs being movable between an undeployed condition and a deployed condition; andthe prongs being configured to engage, at least in part, the area of the second biological tissue.
  • 5. The apparatus of claim 4, wherein: the prongs include: hollow tubes with open portals being configured to face the second biological tissue; andsaid open portals being configured to be embedded, at least in part, into the second biological tissue.
  • 6. The apparatus of claim 4, wherein: the tissue-spreader assembly includes: a first tube; anda second tube configured to be received within, and along, a longitudinal length of the first tube; andthe first tube and the second tube being coaxially aligned with each other after the second tube is received within, and along, the longitudinal length of the first tube; andthe prongs extend past a distal end of the second tube after the prongs are moved from the undeployed condition to the deployed condition.
  • 7. The apparatus of claim 4, wherein: the tissue-spreader assembly includes: a first tube; anda second tube configured to be received within, and along, a longitudinal length of the first tube; andthe first tube and the second tube being coaxially aligned with each other after the second tube is received within, and along, the longitudinal length of the first tube; andthe first tube is configured to maneuver the prongs from the undeployed condition to the deployed condition, once or after the first tube is retracted proximally over the second tube.
  • 8. The apparatus of claim 4, wherein: the tissue-spreader assembly includes: a first tube; anda second tube configured to be received within, and along, a longitudinal length of the first tube; andthe first tube and the second tube being coaxially aligned with each other after the second tube is received within, and along, the longitudinal length of the first tube; andbiased bowed portions, the prongs extending from the biased bowed portions; andthe biased bowed portions being configured to be positioned between the first tube and the second tube after the tissue-spreader assembly is placed in the undeployed condition; andthe biased bowed portions also being configured to be compressed after the tissue-spreader assembly is placed in the undeployed condition.
  • 9. The apparatus of claim 8, wherein: positioned on an outer surface of the second tube are spaced-apart support grooves; andthe spaced-apart support grooves respectively correspond to bowed portions; andthe spaced-apart support grooves are configured to, respectively, selectively receive, and support, the biased bowed portions after the support bowed portions are positioned in the undeployed condition.
  • 10. The apparatus of claim 9, wherein: the prongs extend from the biased bowed portions; andthe prongs terminate at a location distal to an end portion of the second tube.
  • 11. The apparatus of claim 8, wherein: the first tube is configured to force compression of the biased bowed portions, in use, against the second tube once the first tube is moved to cover the biased bowed portions.
  • 12. The apparatus of claim 8, wherein: the first tube is configured to reduce a bow angle formed by the biased bowed portions.
  • 13. The apparatus of claim 8, wherein: the biased bowed portions are set to a shape that bows outwards from the second tube near a distal end of the second tube once the first tube is moved along the patient; andthe first tube is configured to compress and conform the biased bowed portions to an outer surface of the second tube after the first tube is positioned over top of the biased bowed portions.
  • 14. The apparatus of claim 8, wherein: the biased bowed portions are configured to return from a stressed condition to a relaxed condition after the first tube is moved to expose, at least in part, an outer surface of the second tube.
  • 15. The apparatus of claim 1, wherein: the guide path is configured to guide, at least in part, an ancillary device toward the area of the second biological tissue while the area of the second biological tissue remains spread apart by the tissue-spreader assembly and while the first biological tissue remains unengaged with the tissue-spreader assembly.
  • 16. The apparatus of claim 15, wherein: the tissue-spreader assembly also configured to selectively disengage from the area of the second biological tissue after the ancillary device has completed application of treatment to the area of the second biological tissue.
  • 17. The apparatus of claim 15, wherein: the ancillary device being configured to treat the area of the second biological tissue while the area of the second biological tissue remains spread apart by the tissue-spreader assembly.
  • 18. The apparatus of claim 15, wherein: the ancillary device is configured to contact, at least in part, the area of the second biological tissue without contacting the first biological tissue after the area of the second biological tissue is spread apart by the tissue-spreader assembly; andthe ancillary device includes a puncture device configured to impart a puncture force sufficient for puncturing the second biological tissue without puncturing the first biological tissue after the area of the second biological tissue is selectively spread apart by the tissue-spreader assembly.
  • 19. An apparatus, comprising: a tissue-spreader assembly configured to be selectively inserted into a patient having a first biological tissue and a second biological tissue being positioned proximate to the first biological tissue, and to be maneuvered proximate to the second biological tissue; andthe tissue-spreader assembly further configured to selectively engage, at least in part, an area of the second biological tissue without engaging the first biological tissue after the tissue-spreader assembly, in use, is maneuvered proximate to the second biological tissue; andthe tissue-spreader assembly also configured to selectively spread, at least in part, the area of the second biological tissue, and maintain the area of the second biological tissue in a spread-apart condition after the tissue-spreader assembly, in use, selectively engages, at least in part, the area of the second biological tissue without engaging the first biological tissue; wherein:the tissue-spreader assembly includes:prongs being movable between an undeployed condition and a deployed condition; andthe prongs being configured to engage, at least in part, the area of the second biological tissue; and wherein:the prongs include:hollow tubes with open portals being configured to face the second biological tissue; andsaid open portals being configured to be embedded, at least in part, into the second biological tissue.
  • 20. An apparatus, comprising: a tissue-spreader assembly configured to be selectively inserted into a patient having a first biological tissue and a second biological tissue being positioned proximate to the first biological tissue, and to be maneuvered proximate to the second biological tissue; andthe tissue-spreader assembly further configured to selectively engage, at least in part, an area of the second biological tissue without engaging the first biological tissue after the tissue-spreader assembly, in use, is maneuvered proximate to the second biological tissue; andthe tissue-spreader assembly also configured to selectively spread, at least in part, the area of the second biological tissue, and maintain the area of the second biological tissue in a spread-apart condition after the tissue-spreader assembly, in use, selectively engages, at least in part, the area of the second biological tissue without engaging the first biological tissue; wherein:the tissue-spreader assembly includes:a first tube; anda second tube configured to be received within, and along, a longitudinal length of the first tube; andthe first tube and the second tube being coaxially aligned with each other after the second tube is received within, and along, the longitudinal length of the first tube; andbiased bowed portions, the prongs extending from the biased bowed portions; andthe biased bowed portions being configured to be positioned between the first tube and the second tube after the tissue-spreader assembly is placed in the undeployed condition; andthe biased bowed portions also being configured to be compressed after the tissue-spreader assembly is placed in the undeployed condition; wherein:positioned on an outer surface of the second tube are spaced-apart support grooves; andthe spaced-apart support grooves respectively correspond to bowed portions; andthe spaced-apart support grooves are configured to, respectively, selectively receive, and support, the biased bowed portions after the support bowed portions are positioned in the undeployed condition.
US Referenced Citations (315)
Number Name Date Kind
175254 Oberly Mar 1876 A
827626 Gillet Jul 1906 A
848711 Weaver Apr 1907 A
1072954 Junn Sep 1913 A
1279654 Charlesworth Sep 1918 A
1918094 Geekas Jul 1933 A
1996986 Weinberg Apr 1935 A
2021989 De Master Nov 1935 A
2146636 Lipchow Feb 1939 A
3429574 Williams Feb 1969 A
3448739 Stark et al. Jun 1969 A
3575415 Fulp et al. Apr 1971 A
3595239 Petersen Jul 1971 A
4129129 Amrine Dec 1978 A
4244362 Anderson Jan 1981 A
4401124 Guess et al. Aug 1983 A
4639252 Kelly et al. Jan 1987 A
4641649 Walinsky et al. Feb 1987 A
4669467 Willett et al. Jun 1987 A
4682596 Bales et al. Jul 1987 A
4790311 Ruiz Dec 1988 A
4790809 Kuntz Dec 1988 A
4793350 Mar et al. Dec 1988 A
4807620 Strul et al. Feb 1989 A
4832048 Cohen May 1989 A
4840622 Hardy Jun 1989 A
4863441 Lindsay et al. Sep 1989 A
4884567 Elliott et al. Dec 1989 A
4892104 Ito et al. Jan 1990 A
4896671 Cunningham et al. Jan 1990 A
4928693 Goodin et al. May 1990 A
4936281 Stasz Jun 1990 A
4960410 Pinchuk Oct 1990 A
4977897 Hurwitz Dec 1990 A
4998933 Eggers et al. Mar 1991 A
5006119 Acker et al. Apr 1991 A
5019076 Yamanashi et al. May 1991 A
5047026 Rydell Sep 1991 A
5081997 Bosley et al. Jan 1992 A
5098431 Rydell Mar 1992 A
5112048 Kienle May 1992 A
5154724 Andrews Oct 1992 A
5201756 Horzewski et al. Apr 1993 A
5209741 Spaeth May 1993 A
5211183 Wilson May 1993 A
5221256 Mahurkar Jun 1993 A
5230349 Langberg Jul 1993 A
5279575 Sugarbaker Jan 1994 A
5281216 Klicek Jan 1994 A
5300068 Rosar et al. Apr 1994 A
5300069 Hunsberger et al. Apr 1994 A
5314418 Takano et al. May 1994 A
5318525 West et al. Jun 1994 A
5327905 Avitall Jul 1994 A
5364393 Auth et al. Nov 1994 A
5372596 Klicek et al. Dec 1994 A
5380304 Parker Jan 1995 A
5397304 Truckai Mar 1995 A
5403338 Milo Apr 1995 A
5423809 Klicek Jun 1995 A
5425382 Golden et al. Jun 1995 A
5490859 Mische et al. Feb 1996 A
5497774 Swartz et al. Mar 1996 A
5507751 Goode et al. Apr 1996 A
5509411 Littmann et al. Apr 1996 A
5540681 Strul et al. Jul 1996 A
5545200 West et al. Aug 1996 A
5555618 Winkler Sep 1996 A
5571088 Lennox et al. Nov 1996 A
5575766 Swartz et al. Nov 1996 A
5575772 Lennox Nov 1996 A
5599347 Hart et al. Feb 1997 A
5605162 Mirzaee et al. Feb 1997 A
5617878 Taheri Apr 1997 A
5622169 Golden et al. Apr 1997 A
5624430 Eton et al. Apr 1997 A
5667488 Lundquist et al. Sep 1997 A
5673695 McGee et al. Oct 1997 A
5674208 Berg et al. Oct 1997 A
5683366 Eggers et al. Nov 1997 A
5720744 Eggleston et al. Feb 1998 A
5741249 Moss et al. Apr 1998 A
5766135 Terwilliger Jun 1998 A
5779688 Imran et al. Jul 1998 A
5810764 Eggers et al. Sep 1998 A
5814028 Swartz et al. Sep 1998 A
5830214 Flom et al. Nov 1998 A
5836875 Webster, Jr. Nov 1998 A
5849011 Jones et al. Dec 1998 A
5851210 Torossian Dec 1998 A
5885227 Finlayson Mar 1999 A
5888201 Stinson et al. Mar 1999 A
5893848 Negus et al. Apr 1999 A
5893885 Webster, Jr. Apr 1999 A
5904679 Clayman May 1999 A
5916210 Winston Jun 1999 A
5921957 Killion et al. Jul 1999 A
5931818 Werp et al. Aug 1999 A
5944023 Johnson et al. Aug 1999 A
5951482 Winston et al. Sep 1999 A
5957842 Littmann et al. Sep 1999 A
5964757 Ponzi Oct 1999 A
5967976 Larsen et al. Oct 1999 A
5989276 Houser et al. Nov 1999 A
6007555 Devine Dec 1999 A
6009877 Edwards Jan 2000 A
6013072 Winston et al. Jan 2000 A
6017340 Cassidy et al. Jan 2000 A
6018676 Davis et al. Jan 2000 A
6030380 Auth et al. Feb 2000 A
6032674 Eggers et al. Mar 2000 A
6048349 Winston et al. Apr 2000 A
6053870 Fulton, III Apr 2000 A
6053904 Scribner et al. Apr 2000 A
6056747 Saadat et al. May 2000 A
6063093 Winston et al. May 2000 A
6093185 Ellis et al. Jul 2000 A
6106515 Winston et al. Aug 2000 A
6106520 Laufer et al. Aug 2000 A
6117131 Taylor Sep 2000 A
6142992 Cheng et al. Nov 2000 A
6146380 Racz et al. Nov 2000 A
6155264 Ressemann et al. Dec 2000 A
6156031 Aita et al. Dec 2000 A
6171305 Sherman Jan 2001 B1
6179824 Eggers et al. Jan 2001 B1
6193676 Winston et al. Feb 2001 B1
6193715 Wrublewski et al. Feb 2001 B1
6210408 Chandrasekaran et al. Apr 2001 B1
6217575 Devore et al. Apr 2001 B1
6221061 Engelson et al. Apr 2001 B1
6228076 Winston et al. May 2001 B1
6245054 Fuimaono et al. Jun 2001 B1
6267758 Daw et al. Jul 2001 B1
6283983 Makower et al. Sep 2001 B1
6292678 Hall et al. Sep 2001 B1
6293945 Parins et al. Sep 2001 B1
6296615 Brockway et al. Oct 2001 B1
6296636 Cheng et al. Oct 2001 B1
6302898 Edwards et al. Oct 2001 B1
6304769 Arenson et al. Oct 2001 B1
6315777 Comben Nov 2001 B1
6328699 Eigler et al. Dec 2001 B1
6360128 Kordis et al. Mar 2002 B2
6364877 Goble et al. Apr 2002 B1
6385472 Hall et al. May 2002 B1
6394976 Winston et al. May 2002 B1
6395002 Ellman et al. May 2002 B1
6419674 Bowser et al. Jul 2002 B1
6428551 Hall et al. Aug 2002 B1
6450989 Dubrul et al. Sep 2002 B2
6475214 Moaddeb Nov 2002 B1
6485485 Winston et al. Nov 2002 B1
6508754 Liprie et al. Jan 2003 B1
6524303 Garibaldi Feb 2003 B1
6530923 Dubrul et al. Mar 2003 B1
6554827 Chandrasekaran et al. Apr 2003 B2
6562031 Chandrasekaran et al. May 2003 B2
6562049 Norlander et al. May 2003 B1
6565562 Shah et al. May 2003 B1
6607529 Jones et al. Aug 2003 B1
6632222 Edwards et al. Oct 2003 B1
6639999 Cookingham et al. Oct 2003 B1
6650923 Lesh et al. Nov 2003 B1
6651672 Roth Nov 2003 B2
6662034 Segner et al. Dec 2003 B2
6663621 Winston et al. Dec 2003 B1
6702811 Stewart et al. Mar 2004 B2
6709444 Makower Mar 2004 B1
6723052 Mills Apr 2004 B2
6733511 Hall et al. May 2004 B2
6740103 Hall et al. May 2004 B2
6752800 Winston et al. Jun 2004 B1
6755816 Ritter et al. Jun 2004 B2
6811544 Schaer Nov 2004 B2
6814733 Schwartz et al. Nov 2004 B2
6820614 Bonutti Nov 2004 B2
6834201 Gillies et al. Dec 2004 B2
6842639 Winston et al. Jan 2005 B1
6852109 Winston et al. Feb 2005 B2
6855143 Davison et al. Feb 2005 B2
6860856 Ward et al. Mar 2005 B2
6869431 Maguire et al. Mar 2005 B2
6911026 Hall et al. Jun 2005 B1
6951554 Johansen et al. Oct 2005 B2
6951555 Suresh et al. Oct 2005 B1
6955675 Jain Oct 2005 B2
6970732 Winston et al. Nov 2005 B2
6980843 Eng et al. Dec 2005 B2
7029470 Francischelli et al. Apr 2006 B2
7056294 Khairkhahan et al. Jun 2006 B2
7083566 Tornes et al. Aug 2006 B2
7112197 Hartley et al. Sep 2006 B2
7335197 Sage et al. Feb 2008 B2
7618430 Scheib Nov 2009 B2
7651492 Wham Jan 2010 B2
7666203 Chanduszko et al. Feb 2010 B2
7678081 Whiting et al. Mar 2010 B2
7682360 Guerra Mar 2010 B2
7828796 Wong et al. Nov 2010 B2
7900928 Held et al. Mar 2011 B2
8192425 Mirza et al. Jun 2012 B2
8257323 Joseph et al. Sep 2012 B2
8388549 Paul et al. Mar 2013 B2
8500697 Kurth et al. Aug 2013 B2
11339579 Stearns May 2022 B1
20010012934 Chandrasekaran et al. Aug 2001 A1
20010021867 Kordis et al. Sep 2001 A1
20020019644 Hastings et al. Feb 2002 A1
20020022781 Mclntire et al. Feb 2002 A1
20020022836 Goble et al. Feb 2002 A1
20020035361 Houser et al. Mar 2002 A1
20020087153 Roschak et al. Jul 2002 A1
20020087156 Maguire et al. Jul 2002 A1
20020111618 Stewart et al. Aug 2002 A1
20020123749 Jain Sep 2002 A1
20020147485 Mamo et al. Oct 2002 A1
20020169377 Khairkhahan et al. Nov 2002 A1
20020188302 Berg et al. Dec 2002 A1
20020198521 Maguire Dec 2002 A1
20030032929 McGuckin Feb 2003 A1
20030040742 Underwood et al. Feb 2003 A1
20030144658 Schwartz et al. Jul 2003 A1
20030158480 Tornes et al. Aug 2003 A1
20030163153 Scheib Aug 2003 A1
20030225392 McMichael et al. Dec 2003 A1
20040015162 McGaffigan Jan 2004 A1
20040024396 Eggers Feb 2004 A1
20040030328 Eggers et al. Feb 2004 A1
20040044350 Martin et al. Mar 2004 A1
20040073243 Sepetka et al. Apr 2004 A1
20040077948 Violante et al. Apr 2004 A1
20040116851 Johansen et al. Jun 2004 A1
20040127963 Uchida et al. Jul 2004 A1
20040133113 Krishnan Jul 2004 A1
20040133130 Ferry et al. Jul 2004 A1
20040143256 Bednarek Jul 2004 A1
20040147950 Mueller et al. Jul 2004 A1
20040181213 Gondo Sep 2004 A1
20040230188 Cioanta et al. Nov 2004 A1
20050004585 Hall et al. Jan 2005 A1
20050010208 Winston et al. Jan 2005 A1
20050049628 Schweikert et al. Mar 2005 A1
20050059966 Mcclurken et al. Mar 2005 A1
20050065507 Hartley et al. Mar 2005 A1
20050085806 Auge et al. Apr 2005 A1
20050096529 Cooper et al. May 2005 A1
20050101984 Chanduszko et al. May 2005 A1
20050119556 Gillies et al. Jun 2005 A1
20050137527 Kunin Jun 2005 A1
20050149012 Penny et al. Jul 2005 A1
20050203504 Wham et al. Sep 2005 A1
20050203507 Truckai et al. Sep 2005 A1
20050261607 Johansen et al. Nov 2005 A1
20050288631 Lewis et al. Dec 2005 A1
20060041253 Newton et al. Feb 2006 A1
20060074398 Whiting et al. Apr 2006 A1
20060079769 Whiting et al. Apr 2006 A1
20060079787 Whiting et al. Apr 2006 A1
20060079884 Manzo et al. Apr 2006 A1
20060085054 Zikorus et al. Apr 2006 A1
20060089638 Carmel et al. Apr 2006 A1
20060106375 Werneth et al. May 2006 A1
20060135962 Kick et al. Jun 2006 A1
20060142756 Davies et al. Jun 2006 A1
20060189972 Grossman Aug 2006 A1
20060241586 Wilk Oct 2006 A1
20060247672 Vidlund et al. Nov 2006 A1
20060264927 Ryan Nov 2006 A1
20060276710 Krishnan Dec 2006 A1
20070060879 Weitzner et al. Mar 2007 A1
20070066975 Wong et al. Mar 2007 A1
20070118099 Trout, III May 2007 A1
20070123964 Davies et al. May 2007 A1
20070167775 Kochavi et al. Jul 2007 A1
20070208256 Marilla Sep 2007 A1
20070213595 Ravikumar Sep 2007 A1
20070225681 House Sep 2007 A1
20070270791 Wang et al. Nov 2007 A1
20080039865 Shaher et al. Feb 2008 A1
20080042360 Veikley Feb 2008 A1
20080086120 Mirza et al. Apr 2008 A1
20080097213 Carlson et al. Apr 2008 A1
20080108987 Bruszewski et al. May 2008 A1
20080146918 Magnin et al. Jun 2008 A1
20080171934 Greenan et al. Jul 2008 A1
20080208121 Youssef et al. Aug 2008 A1
20080275439 Francischelli et al. Nov 2008 A1
20090105742 Kurth et al. Apr 2009 A1
20090138009 Viswanathan et al. May 2009 A1
20090163850 Betts et al. Jun 2009 A1
20090177114 Chin et al. Jul 2009 A1
20090264977 Bruszewski et al. Oct 2009 A1
20100087789 Leeflang et al. Apr 2010 A1
20100125282 Machek et al. May 2010 A1
20100168684 Ryan Jul 2010 A1
20100179632 Bruszewski et al. Jul 2010 A1
20100191142 Paul et al. Jul 2010 A1
20100194047 Sauerwine Aug 2010 A1
20110046619 Ducharme Feb 2011 A1
20110152716 Chudzik et al. Jun 2011 A1
20110160592 Mitchell Jun 2011 A1
20110190763 Urban et al. Aug 2011 A1
20120232546 Mirza et al. Sep 2012 A1
20120265055 Melsheimer et al. Oct 2012 A1
20120330156 Brown et al. Dec 2012 A1
20130184551 Paganelli et al. Jul 2013 A1
20130184735 Fischell et al. Jul 2013 A1
20130282084 Mathur et al. Oct 2013 A1
20140206987 Urbanski et al. Jul 2014 A1
20140296769 Hyde et al. Oct 2014 A1
20160206338 Allen et al. Jul 2016 A1
20160220741 Garrison et al. Aug 2016 A1
20190021763 Zhou et al. Jan 2019 A1
20190247035 Gittard et al. Aug 2019 A1
Non-Patent Literature Citations (1)
Entry
Rook Epicardial Access Device Study, ClinicalTrials.gov Identifier: NCT03427333, https://clinicaltrials.gov/ct2/show/NCT03427333, First Posted Online : Feb. 9, 2018.
Related Publications (1)
Number Date Country
20210393249 A1 Dec 2021 US
Provisional Applications (1)
Number Date Country
63040593 Jun 2020 US